Myeong Jun Song
Quick facts
Marketed products
- Daclatasvir plus Asunaprevir · Infectious Disease (Hepatology)
Daclatasvir and asunaprevir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS3 protease, respectively, blocking viral replication.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: